Metabolomic Profiling of Prostate Cancer Progression During Active Surveillance
JOHNS HOPKINS UNIV BALTIMORE MD SCHOOL OF MEDICINE
Pagination or Media Count:
This report covers the second year of funding of this project. The goal of the project is to identify a metabolomics signature, measured on biopsy tissue, serum, or urine, that can distinguish men with only Gleason score 6 tumor in their prostate vs. men whose biopsy indicates Gleason score 6 but who harbor higher grade Gleason score 7 tumor that was not sampled by the biopsy. This report deals largely with modifications to the study to accommodate the unfortunate death of the study Research Nurse, and the development of a metabolomics signature for aggressive disease by our industry partner, Metabolon, Inc. These events have caused a shift of focus for Aim 1 to validation of the Metabolon signature rather than discovery of a new signature, and de-emphasized the need for frozen tissue in favor of matched urine and serum. With these changes we anticipate being able to complete the study and achieve our planned objective determining whether a metabolomics signature can discriminate men who can vs. cannot safely be offered active surveillance - by the end of Year 3.
- Medicine and Medical Research